1 billion large varieties!

Recently, Kelun Pharmaceutical and Osaikang have entered the administrative examination and approval stage with the generic 4 types of lenvatinib mesylate capsules, and they are expected to be approved for listing in the near future
.
Lenvatinib is a star drug for liver cancer, with sales of 1.
178 billion yuan in the Chinese market in 2020
.
Lenvatinib is a multi-target receptor tyrosine kinase inhibitor developed by Eisai/Mersk.
Its targets include VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET, etc.
, in September 2018 China was approved to be marketed for the treatment of patients with hepatocellular carcinoma
.
Sales of lenvatinib have been rising since it went on the market
.
According to the financial reports of Eisai and Merck & Co.
, the total global sales of lenvatinib in 2020 will exceed 1.
8 billion U.
S.
dollars
.
In the Chinese market, lenvatinib sales rose from 189 million yuan in 2018 to 1.
178 billion yuan in 2020
.
In less than three years, lenvatinib has grown into a one-billion-level single product
.
Eisai lenvatinib sales in China (unit: million yuan) Source: Mynet.
com's multinational listed company sales database.
At present, 13 domestic companies’ lenvatinib generic drugs have been declared for listing.
Chia Tai Tianqing, Simcere Pharmaceuticals Obtained the production approval on July 20, 2021, and tied for the first domestic imitation; Nanjing Zhengda Tianqing, Qilu Pharmaceutical, and Better Pharmaceuticals have subsequently obtained approval for the product to go on the market
.
The source of the approval status of lenvatinib mesylate capsules: One-click search on Mynet.
com.
The registration status of lenvatinib mesylate capsules of Kelun Pharmaceutical and Osaikon was changed to "under approval" on the same day.
If successful Pianjiang was deemed to have passed the review and became the sixth domestically produced company
.
Data source: Mi Neiwang database, NMPA